Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 7;402(10409):1251-1260.
doi: 10.1016/S0140-6736(23)01700-2.

Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study

Deb Schrag  1 , Tomasz M Beer  2 , Charles H McDonnell 3rd  3 , Lincoln Nadauld  4 , Christina A Dilaveri  5 , Robert Reid  6 , Catherine R Marinac  7 , Karen C Chung  8 , Margarita Lopatin  8 , Eric T Fung  8 , Eric A Klein  8
Affiliations

Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study

Deb Schrag et al. Lancet. .

Abstract

Background: Multicancer early detection (MCED) blood tests can detect a cancer signal from circulating cell-free DNA (cfDNA). PATHFINDER was a prospective cohort study investigating the feasibility of MCED testing for cancer screening.

Methods: In this prospective cohort study done in oncology and primary care outpatient clinics at seven US health networks, a convenience sample of adults aged 50 years or older without signs or symptoms of cancer consented to MCED testing. We collected blood, analysed cfDNA, and returned results to participants' doctors. If a methylation signature indicative of cancer was detected, predicted cancer signal origin(s) informed diagnostic assessment. The primary outcome was time to, and extent of, diagnostic testing required to confirm the presence or absence of cancer. This trial is registered at ClinicalTrials.gov, NCT04241796, and is completed.

Findings: Between Dec 12, 2019, and Dec 4, 2020, we recruited 6662 participants. 4204 (63·5%) of 6621 participants with analysable results were women, 2417 (36·5%) were men, and 6071 (91·7%) were White. A cancer signal was detected in 92 (1·4%) of 6621 participants with analysable results. 35 (38%) participants were diagnosed with cancer (true positives) and 57 (62%) had no cancer diagnosis (false positives). Excluding two participants whose diagnostic assessments began before MCED test results were reported, median time to diagnostic resolution was 79 days (IQR 37-219): 57 days (33-143) in true-positive and 162 days (44-248) in false-positive participants. Most participants had both laboratory tests (26 [79%] of 33 with true-positive results and 50 [88%] of 57 with false-positive results) and imaging (30 [91%] of 33 with true-positive results and 53 [93%] of 57 with false-positive results). Fewer procedures were done in participants with false-positive results (17 [30%] of 57) than true-positive results (27 [82%] of 33) and few had surgery (one with a false-positive result and three with a true-positive result).

Interpretation: This study supports the feasibility of MCED screening for cancer and underscores the need for further research investigating the test's clinical utility.

Funding: GRAIL.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests DS reports an uncompensated advisory role and serving as a study investigator with research funding to Dana Farber Cancer Institute (GRAIL) and personal fees for editorial service (Journal of the American Medical Association). TMB reports a consultant agreement with GRAIL, AbbVie, Amgen, Arvinas, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squib, Constellation, Dantari Pharmaceuticals, GlaxoSmithKline, Janssen, Myovant Sciences, Pfizer, Sanofi, and Sapience Therapeutics; and reports stock ownership in Arvinas, Salarius Pharmaceuticals, and Exact Sciences. CHM reports a consultant agreement with GRAIL. LN reports stock ownership in Culmination Bio. KCC reports stock ownership in Illumina, Bristol Myers Squib, Gilead, Baxter, and Bayer, and is an employee of GRAIL. ETF and ML report stock ownership of Illumina and are employees of GRAIL. EAK is an employee of GRAIL. All other authors declare no competing interests.

Figures

Figure 1:
Figure 1:
Trial profile Participant flow diagram, including true positive analysis sets for outcomes with variable participant numbers to the left. CSO=cancer signal origin. EOS=end of study. TP=true positives.
Figure 2:
Figure 2:
Time to diagnostic resolution for participants with cancer signal detected (n=90)
Figure 3.
Figure 3.
Extent of diagnostic testing in participants with cancer signal detected
Figure 4:
Figure 4:
Cancer diagnosed after a positive MCED result The 36 cancers diagnosed in the 35 true positive participants are depicted by a dot in the organ/system in which the cancer was found. Histology details are given when available. Of the 29 participants with new cancers, 14 (48%) were Stage I or II. Overall 74% cancers detected lack current USPSTF-recommendations for screening tests. c=clinical staging/diagnosis. c/w=consistent with. MCED=multi-cancer early detection. R(L)=recurrent local cancer. R(M)=recurrent metastatic cancer. USPSTF=United States Preventive Services Task Force.
See this image and copyright information in PMC

Comment in

References

    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73(1):17–48. - PubMed
    1. Hackshaw A, Cohen SS, Reichert H, Kansal AR, Chung KC, Ofman JJ. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Br J Cancer. 2021;125(10):1432–42. - PMC - PubMed
    1. Clarke CA, Hubbell E, Kurian AW, Colditz GA, Hartman AR, Gomez SL. Projected Reductions in Absolute Cancer-Related Deaths from Diagnosing Cancers Before Metastasis, 2006–2015. Cancer Epidemiol Biomarkers Prev 2020;29(5):895–902. - PubMed
    1. Beer TM. Novel blood-based early cancer detection: diagnostics in development. Am J Manag Care 2020;26(14 Suppl):S292–S9. - PubMed
    1. Liu MC. Transforming the landscape of early cancer detection using blood tests-Commentary on current methodologies and future prospects. Br J Cancer. 2021;124(9):1475–7. - PMC - PubMed

Publication types

Substances

Associated data

LinkOut - more resources